Broadcast Date: July 16, 2019
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
For the past two decades, the paradigm in the field has been “one biomarker, one drug,” leading to the development of many targeted therapies and companion diagnostics. As molecular profiling of various cancer types expands, we imagine the use of multiple biomarkers for a combination therapy, like a targeted therapy and immunotherapy together, or even for a monotherapy.
In this roundtable our panelists will discuss assessing the validity of biomarkers to inform drug development and potential combination therapies. Key considerations include predictive testing of biomarkers, analytical methods, drug-diagnostic co-development and potential reimbursement considerations. Dr. Kelly Sullivan, Solutions Manager, N-of-One (a QIAGEN Company) will moderate the discussion with Jeffrey Waldron, Executive Director, Precision Medicine Connective, and Dr. Diana Merino, Science Policy Analyst at Friends of Cancer Research. The panel discussion will be followed by a live audience Q&A.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
Diana Merino, PhD
Science Policy Analyst
Friends of Cancer Research
Jeffrey Waldron
Executive Director
Friends of Cancer Research
E. Kelly Sullivan, PhD
Solutions Manager
N-of-One, Inc.
The post Managing Multiple Biomarker Therapeutic Development appeared first on GEN – Genetic Engineering and Biotechnology News.
